Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Ultragenyx Pharmaceutical Inc.

RARE Nasdaq Pharmaceutical Preparations Financials FY2016โ€“FY2025

Last close ยท Oct 23, 2026

$15.65

1.9%
Compare
Revenue Total sales reported in the income statement.
$673M
20.2% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’79.5%
16.2ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$575M
Free cash flow Cash from operations minus capital spending.
โˆ’$472M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$1.6B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$5.83 EPS (TTM)

What Ultragenyx Pharmaceutical Inc. does

No business description yet.

Legal name
Ultragenyx Pharmaceutical Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 18, 2026
Accession ยท CIK
0001193125-26-057329
0001515673

Revenue and margins

Ultragenyx Pharmaceutical Inc. had $673M of revenue in fiscal 2025, up 20.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$472M in fiscal 2025, โˆ’70.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Ultragenyx Pharmaceutical Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 9.0%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Ultragenyx Pharmaceutical Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $740M$748M$578M$610M$680M
Current ratio 4.7x3.4x2.6x2.4x2.5x
Quick ratio 4.6x3.3x2.5x2.2x2.3x
Total assets $1.5B$1.5B$1.5B$1.5B$1.5B
Total liabilities $600M$1.2B$1.2B$1.2B$1.6B
Shareholders' equity $923M$352M$275M$255Mโˆ’$80.0M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ• โœ“ โœ• โœ“ โœ• โœ• โœ“ โœ“ โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ• โœ“ โœ“ โœ• โœ• โœ• โœ• โœ• โœ“
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โœ• โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
F-score โ€” / 32 / 73 / 83 / 73 / 72 / 72 / 73 / 73 / 74 / 7
Accruals ratio โˆ’15.7%โˆ’9.4%15.4%โˆ’6.2%โˆ’3.8%โˆ’7.0%โˆ’21.3%โˆ’8.7%โˆ’10.4%โˆ’7.2%
Altman Z'' 5.33โˆ’3.631.72โˆ’0.881.86โˆ’1.60โˆ’5.74โˆ’7.75โˆ’8.70โˆ’9.62

10 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $0.1M $2.6M $51.5M $104M $271M $351M $363M $434M $560M $673M
Gross profit โ€” $2.6M $50.3M โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Research and development $183M $232M $294M $357M $412M $497M $706M $648M $698M $750M
Operating income โˆ’$248M โˆ’$329M โˆ’$371M โˆ’$424M โˆ’$330M โˆ’$382M โˆ’$649M โˆ’$569M โˆ’$536M โˆ’$535M
Pretax income โˆ’$246M โˆ’$318M โˆ’$197M โˆ’$399M โˆ’$185M โˆ’$453M โˆ’$702M โˆ’$609M โˆ’$567M โˆ’$571M
Income tax $0.0M โˆ’$16.2M $0.5M $3.3M $1.2M $1.0M $5.7M โˆ’$2.0M $2.0M $4.0M
Net income โˆ’$246M โˆ’$302M โˆ’$198M โˆ’$403M โˆ’$187M โˆ’$454M โˆ’$707M โˆ’$607M โˆ’$569M โˆ’$575M
Net income to common โˆ’$246M โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Diluted EPS โˆ’$6.21 โˆ’$7.12 โˆ’$3.97 โˆ’$7.12 โˆ’$3.07 โˆ’$6.70 โˆ’$10.12 โˆ’$8.25 โˆ’$6.29 โˆ’$5.83
Diluted shares 0.04B 0.04B 0.05B 0.06B 0.06B 0.07B 0.07B 0.07B 0.09B 0.10B
Cash flow
Cash from operations โˆ’$161M โˆ’$254M โˆ’$291M โˆ’$345M โˆ’$132M โˆ’$339M โˆ’$380M โˆ’$475M โˆ’$414M โˆ’$466M
Capital expenditure $10.2M $2.8M $4.1M $24.8M $43.9M $73.1M $116M $44.0M $7.0M $6.0M
Free cash flow โˆ’$171M โˆ’$257M โˆ’$295M โˆ’$370M โˆ’$176M โˆ’$412M โˆ’$497M โˆ’$519M โˆ’$421M โˆ’$472M
Depreciation and amortization $3.4M $5.8M $19.5M $8.5M $12.3M $13.2M $18.2M $26.0M $36.0M $35.0M
Stock-based compensation $48.3M $68.0M $80.1M $82.0M $85.7M $105M $130M $135M $158M $153M
Acquisitions โ€” $143M โ€” โ€” $0.0M $0.0M $75.0M $0.0M $0.0M โ€”
Balance sheet
Cash and short-term investments $380M $234M $460M $755M $1.2B $740M $748M $578M $610M $680M
Finance lease liabilities โ€” โ€” โ€” โ€” $1.2M $1.0M $0.2M โ€” โ€” โ€”
Current assets $402M $270M $522M $851M $1.3B $857M $884M $732M $817M $951M
Current liabilities $60.3M $71.0M $74.7M $103M $190M $181M $261M $280M $344M $384M
Inventory โ€” $0.8M $7.1M $11.5M $13.0M $16.2M $26.8M $34.0M $45.0M $52.0M
Property and equipment, net $17.1M $21.8M $20.0M $44.3M $73.5M $141M $260M $291M $266M $244M
Goodwill โ€” $44.4M $44.4M $44.4M $44.4M $44.4M $44.4M $44.4M $44.0M $44.0M
Intangible assets โ€” $142M $129M $129M $131M $131M $160M $166M $178M $176M
Total assets $541M $491M $720M $1.1B $1.8B $1.5B $1.5B $1.5B $1.5B $1.5B
Total liabilities $66.7M $107M $111M $482M $605M $600M $1.2B $1.2B $1.2B $1.6B
Preferred stock โ€” โ€” โ€” โ€” โ€” $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $474M $383M $609M $654M $1.2B $923M $352M $275M $255M โˆ’$80.0M
Margins
Gross margin โ€” 100.0% 97.8% โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Operating margin โˆ’186,471.4% โˆ’12,593.5% โˆ’721.2% โˆ’409.0% โˆ’121.8% โˆ’108.6% โˆ’178.6% โˆ’131.1% โˆ’95.7% โˆ’79.5%
EBITDA margin โˆ’183,897.0% โˆ’12,370.5% โˆ’683.2% โˆ’400.8% โˆ’117.3% โˆ’104.9% โˆ’173.6% โˆ’125.1% โˆ’89.3% โˆ’74.3%
Net margin โˆ’184,867.7% โˆ’11,567.3% โˆ’383.7% โˆ’388.3% โˆ’68.8% โˆ’129.2% โˆ’194.7% โˆ’139.9% โˆ’101.6% โˆ’85.4%
FCF margin โˆ’128,694.0% โˆ’9,825.3% โˆ’572.2% โˆ’357.0% โˆ’65.0% โˆ’117.2% โˆ’136.7% โˆ’119.6% โˆ’75.2% โˆ’70.1%
Returns
Return on capital employed โˆ’51.6% โˆ’78.4% โˆ’57.6% โˆ’41.1% โˆ’21.0% โˆ’28.5% โˆ’50.5% โˆ’47.0% โˆ’46.2% โˆ’46.6%
Return on equity โˆ’51.9% โˆ’70.5% โˆ’39.8% โˆ’63.8% โˆ’20.6% โˆ’43.7% โˆ’111.0% โˆ’193.6% โˆ’214.7% โˆ’657.1%
Return on assets โˆ’45.5% โˆ’58.6% โˆ’32.7% โˆ’43.4% โˆ’12.9% โˆ’27.7% โˆ’46.1% โˆ’40.0% โˆ’38.0% โˆ’37.9%
Return on tangible equity โˆ’51.9% โˆ’153.0% โˆ’45.4% โˆ’83.8% โˆ’19.1% โˆ’60.7% โˆ’479.6% โˆ’943.7% โˆ’1,724.2% โ€”
Growth
Revenue growth โ€” 1,863.9% 1,871.5% 101.4% 161.3% 29.7% 3.4% 19.5% 29.0% 20.2%
Share count change โ€” 7.2% 17.2% 13.7% 7.5% 11.4% 3.1% 5.1% 23.1% 9.0%
Financial health
Current ratio 6.7x 3.8x 7.0x 8.2x 6.8x 4.7x 3.4x 2.6x 2.4x 2.5x
Quick ratio 6.7x 3.8x 6.9x 8.1x 6.8x 4.6x 3.3x 2.5x 2.2x 2.3x
Capital allocation
Capex / revenue 7,660.2% 106.9% 7.9% 23.9% 16.2% 20.8% 32.0% 10.1% 1.3% 0.9%
Stock comp / revenue 36,322.6% 2,603.9% 155.6% 79.1% 31.6% 29.9% 35.9% 31.1% 28.2% 22.7%
Quality scores
Piotroski F-score โ€” 2.0 3.0 3.0 3.0 2.0 2.0 3.0 3.0 4.0
Altman Z'' 5.3 โˆ’3.6 1.7 โˆ’0.9 1.9 โˆ’1.6 โˆ’5.7 โˆ’7.7 โˆ’8.7 โˆ’9.6
Accruals ratio โˆ’15.7% โˆ’9.4% 15.4% โˆ’6.2% โˆ’3.8% โˆ’7.0% โˆ’21.3% โˆ’8.7% โˆ’10.4% โˆ’7.2%

Source: SEC EDGAR XBRL filings (CIK 0001515673). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open